Comrade Ma Xu has won many scientific and technological awards such as the Outstanding Scientific and Technological Achievement Award of the National "Ninth Five-Year Plan" Key Scientific and Technological Research Plan and the First Prize of the National Family Planning Commission's Scientific and Technological Progress Award; in addition, "New Non-Injurious Prenatal Diagnosis" "Research on Pathways" and "Exploration of New Diseases and New Methods for Prenatal Genetic Diagnosis of Disabling Genetic Diseases" were both rated by the National Family Planning Commission as one of the ten major scientific and technological achievements in national family planning/reproductive health during the "Ninth Five-Year Plan" period. He took the lead in starting a series of scientific and technological research and research on new technologies and methods for non-invasive prenatal diagnosis in China, published a number of academic papers, and obtained a number of invention patents; in the most common hereditary intellectual disability in humans - Down syndrome In terms of prevention and control of pregnancy syndrome, we have established technologies for serological screening and dried blood film screening in the first and second trimesters of pregnancy, built the only database in China that can be used for clinical risk identification, screened a total of 80,000 pregnant women, and established corresponding National standard products, domestic and foreign experts are being organized to compile academic monographs in this area; in terms of prevention and control of congenital rubella syndrome, seroepidemiological studies have been conducted on populations in major representative regions of my country (including cities, rural areas, pastoral areas, etc.) The survey clarified for the first time the population distribution of rubella virus antibody titers in women of childbearing age in my country, successfully developed a method for measuring the immunity of rubella virus in women of childbearing age, developed the corresponding national standards and has been officially used, and at the same time conducted a congenital test in Shenzhen Comprehensive pilot study of community intervention technology for rubella syndrome, and based on this, the Shenzhen three-level birth defects intervention network was established, realizing networked technical management. The project's practice in Shenzhen won the second prize for scientific and technological progress; In addition, Comrade Ma Xu has also done a lot of work in applying non-invasive prenatal diagnosis technology to the prevention of mother-child Rh blood group incompatibility, as well as searching for markers and establishing new methods for breast cancer, ovarian cancer and cervical cancer screening. Researched, published many papers, and obtained a number of invention patents.
Finally, during the SARS epidemic in my country, Comrade Ma Xu led his research team to establish differential diagnosis technology for eight common viruses that cause SARS, including SARS coronavirus, and based on In accordance with the technical requirements promulgated by the State Drug Administration, clinical trial research was conducted in conjunction with the People's Liberation Army General Hospital, Xiaotangshan Field Hospital, Peking University First Hospital, Union Medical College and other units, and the invention patents and software copyrights were formed and officially submitted to the National Drug Administration. The Supervision and Administration Bureau made a declaration. This product is the only product in China that can be used for the differential diagnosis of SARS pathogens, and its clinical trial results have been specially introduced at the WHO international conference on SARS. In short, Comrade Ma Xu’s academic research fields range from the etiology of birth defects and major reproductive health diseases, the research and development of key prevention and treatment technologies, the industrialization of biotech drugs, prevention and treatment programs, and the study of corresponding technical standards, and thus formed A scientific and technological innovation chain focusing on birth defect intervention and prevention and treatment of major reproductive health diseases has been established.
In terms of the transformation and industrialization of scientific and technological achievements, Comrade Ma Xu paid special attention to the transformation of scientific and technological achievements into real productivity. Among them, a technical achievement of maternal and child Rh blood type diagnosis technology received 6 million yuan after transformation, and was On this basis, an experimental base that complies with national biotechnology product development standards has been established, laying the foundation for further research and development of reproductive health-related biotechnology products. The prenatal diagnosis project developed by Comrade Ma Xu has been registered as a biotechnology company in Zhongguancun High-tech Industrial Park and serves as the company's chief scientist. He directly leads the transformation and industrialization of an independent series of bio-high-tech patent results. The company has been approved by the Beijing Municipal Government The Science and Technology Commission has identified it as a high-tech enterprise in Beijing. At the same time, the enterprise is also the unit responsible for the national key scientific and technological research plan during the “Tenth Five-Year Plan”. Among them, the Down syndrome prenatal screening system has completed 17,000 clinical trials and has been submitted to The National Medical Products Administration applied, and the human papillomavirus liquid phase chip detection system also completed clinical trials; at the National Population and Family Planning Commission Birth Defects Intervention Engineering Technology Research Center, the SARS pathogen identification and diagnosis system was developed and the invention was applied for Patent and has entered the application process. In terms of cooperation with domestic and foreign biotechnology companies, there are horizontal cooperation projects with internationally renowned biotechnology companies such as the United States and Japan, as well as well-known domestic biotechnology companies, and this kind of cooperation has great significance in accelerating the transformation and industrialization of scientific and technological achievements. promotion effect.
In terms of scientific and technological management and institutional innovation, Comrade Ma Xu took the lead in implementing a number of enterprise management measures such as the appointment system, incentive elimination mechanism, and full cost accounting management at the National Population and Family Planning Commission’s Birth Defects Intervention Engineering Technology Research Center under his leadership. At the same time, he established Full-time staff for intellectual property and human resources management; the center has only 4 permanent staff, 15 external scientific and technical personnel (including 3 professors and 2 PhDs), 3 external management staff, 13 postgraduate students and 3 PhD students . Comrade Ma Xu strives to further explore ways to transform scientific and technological achievements that are in line with the laws of the market economy and the laws of the development of science and technology itself, to improve the level of scientific and technological management through institutional and mechanism innovation, to drive scientific and technological innovation through institutional innovation, and ultimately to achieve a virtuous cycle of talent, technology and economic operations. .